Drug Database
Back to search

Netherlands· NL-373dd8a5cef6

Lamivudine/Zidovudine Viatris 150/300 mg, filmomhulde tabletten

A zidovudine and lamivudine product containing lamivudine 0-water + zidovudine, registered in Netherlands by Viatris Limited. The same ATC class is registered in 14 of our 19 countries.

ATC J05AR01

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedLamivudine/Zidovudine Viatris 150/300…ATCJ05AR01REGISTER NO.NL-373dd8a5cef6PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lamivudine 0-water + zidovudineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Zidovudine and lamivudine is registered in 14 of 19 countries.

Countries holding a registration under ATC J05AR01 (zidovudine and lamivudine), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search zidovudine and lamivudine products by name

Zidovudine and lamivudine · ATC J05AR01

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
LAMIVUDINE 0-WATER + ZIDOVUDINE
Manufacturer
Viatris Limited
Country
Netherlands (NL)
ATC code
J05AR01
ATC class
Zidovudine and lamivudine
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    107779

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

1 interaction on record for zidovudine and lamivudine.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check zidovudine and lamivudine against other medicinesHow interaction checks work

Zidovudine and lamivudine · interactions on record

1 record

1 more interaction with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Zidovudine and lamivudine in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All zidovudine and lamivudine products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Belgium · Lamivudine/Zidovudine Viatris
  • Cyprus · Lamivudine/Zidovudine Aurobindo
  • Germany · Lamivudin/Zidovudin, Lamivudin/Zidovudin Accord
  • France · Lamivudine/Zidovudine Arrow, Lamivudine/Zidovudine Viatris
  • United Kingdom (Northern Ireland) · Lamivudine/Zidovudine Milpharm, Lamivudine/Zidovudine Mylan
  • Iceland · Combivir
  • Italy · Lamivudina E Zidovudina Aurobindo, Lamivudina E Zidovudina Mylan
  • Liechtenstein · Combivir
  • Luxembourg · Lamivudine/Zidovudine Viatris
  • Malta · Lamivudine/Zidovudine Mylan
  • Norway · Combivir
  • Portugal · Lamivudina + Zidovudina Accord, Lamivudina + Zidovudina Aurobindo
  • Romania · Lamivudină/Zidovudină Aurobindo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/dee1f91e-e554-4628-9361-b6dc050bd93e
GET /v1/drugs/dee1f91e-e554-4628-9361-b6dc050bd93e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": "RVG",
  "source": "cbg_meb",
  "smpc_url": "https://www.geneesmiddeleninformatiebank.nl/smpc/h107779_smpc.pdf",
  "strength": null,
  "atc_label": "Zidovudine And Lamivudine",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/rvg107779",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "HYPROMELLOSE (E 464)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMZETMEELGLYCOLAAT",
    "PROPYLEENGLYCOL (E 1520)",
    "SILICIUMDIOXIDE (E 551)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "LAMIVUDINE 0-WATER",
    "ZIDOVUDINE"
  ],
  "leaflet_url": "https://www.geneesmiddeleninformatiebank.nl/bijsluiters/h107779.pdf",
  "authorised_at": "2011/08/31",
  "procedure_number": "NL/H/2059/001",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "107779",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about zidovudine and lamivudine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console